Cargando…
Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs
The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868525/ https://www.ncbi.nlm.nih.gov/pubmed/24367248 http://dx.doi.org/10.1371/journal.pcbi.1003395 |
_version_ | 1782296462554562560 |
---|---|
author | Blachly, Patrick G. de Oliveira, César A. F. Williams, Sarah L. McCammon, J. Andrew |
author_facet | Blachly, Patrick G. de Oliveira, César A. F. Williams, Sarah L. McCammon, J. Andrew |
author_sort | Blachly, Patrick G. |
collection | PubMed |
description | The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4S] protein responsible for converting HMBPP to IPP and DMAPP in the ultimate step in the nonmevalonate pathway. By performing accelerated molecular dynamics simulations on both substrate-free and HMBPP-bound [Fe(4)S(4)](2+) IspH, we elucidate how substrate binding alters the dynamics of the protein. Using principal component analysis, we note that while substrate-free IspH samples various open and closed conformations, the closed conformation observed experimentally for HMBPP-bound IspH is inaccessible in the absence of HMBPP. In contrast, simulations with HMBPP bound are restricted from accessing the open states sampled by the substrate-free simulations. Further investigation of the substrate-free simulations reveals large fluctuations in the HMBPP binding pocket, as well as allosteric pocket openings – both of which are achieved through the hinge motions of the individual domains in IspH. Coupling these findings with solvent mapping and various structural analyses reveals alternative druggable sites that may be exploited in future drug design efforts. |
format | Online Article Text |
id | pubmed-3868525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38685252013-12-23 Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs Blachly, Patrick G. de Oliveira, César A. F. Williams, Sarah L. McCammon, J. Andrew PLoS Comput Biol Research Article The nonmevalonate pathway is responsible for isoprenoid production in microbes, including H. pylori, M. tuberculosis and P. falciparum, but is nonexistent in humans, thus providing a desirable route for antibacterial and antimalarial drug discovery. We coordinate a structural study of IspH, a [4Fe-4S] protein responsible for converting HMBPP to IPP and DMAPP in the ultimate step in the nonmevalonate pathway. By performing accelerated molecular dynamics simulations on both substrate-free and HMBPP-bound [Fe(4)S(4)](2+) IspH, we elucidate how substrate binding alters the dynamics of the protein. Using principal component analysis, we note that while substrate-free IspH samples various open and closed conformations, the closed conformation observed experimentally for HMBPP-bound IspH is inaccessible in the absence of HMBPP. In contrast, simulations with HMBPP bound are restricted from accessing the open states sampled by the substrate-free simulations. Further investigation of the substrate-free simulations reveals large fluctuations in the HMBPP binding pocket, as well as allosteric pocket openings – both of which are achieved through the hinge motions of the individual domains in IspH. Coupling these findings with solvent mapping and various structural analyses reveals alternative druggable sites that may be exploited in future drug design efforts. Public Library of Science 2013-12-19 /pmc/articles/PMC3868525/ /pubmed/24367248 http://dx.doi.org/10.1371/journal.pcbi.1003395 Text en © 2013 Blachly et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Blachly, Patrick G. de Oliveira, César A. F. Williams, Sarah L. McCammon, J. Andrew Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs |
title | Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs |
title_full | Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs |
title_fullStr | Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs |
title_full_unstemmed | Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs |
title_short | Utilizing a Dynamical Description of IspH to Aid in the Development of Novel Antimicrobial Drugs |
title_sort | utilizing a dynamical description of isph to aid in the development of novel antimicrobial drugs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868525/ https://www.ncbi.nlm.nih.gov/pubmed/24367248 http://dx.doi.org/10.1371/journal.pcbi.1003395 |
work_keys_str_mv | AT blachlypatrickg utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs AT deoliveiracesaraf utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs AT williamssarahl utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs AT mccammonjandrew utilizingadynamicaldescriptionofisphtoaidinthedevelopmentofnovelantimicrobialdrugs |